Introduction {#sec1-2152656719892844}
============

Anaphylactoid reactions to iodinated intravenous (IV) radiographic contrast material (RCM) are rare and may be life-threatening in approximately one-tenth percent (0.1%) of reactions.^[@bibr1-2152656719892844]^ Desensitization is a validated preventative measure for anaphylaxis or anaphylactoid reactions. Several studies offer data on the efficacy of RCM desensitization for medical emergencies, such as cardiac catheterization.^[@bibr2-2152656719892844][@bibr3-2152656719892844]--[@bibr4-2152656719892844]^ Frequently, the cardiac catheterization schedule does not accommodate the RCM desensitization protocol. We propose an RCM desensitization protocol to meet the catheterization schedule without losing the protective nature of the desensitization.

Case Report {#sec2-2152656719892844}
===========

The patient previously described by Uppal et al. required a repeat catheterization due to unstable angina with RCM desensitization 2 years after the initial procedure.^[@bibr2-2152656719892844]^ The patient was pretreated with prednisone, diphenhydramine (Bendaryl®), and ranitidine. Following the protocol reported by Uppal et al.,^[@bibr2-2152656719892844]^ the patient tolerated doses 1 and 2 and subsequently developed pruritus minutes after the third dose ([Table 1](#table1-2152656719892844){ref-type="table"}). Fifty milligram of IV diphenhydramine was administered, resulting in the improvement of pruritus. Doses 2 and 3 were then repeated. The patient developed diffuse pruritus with the administration of dose 4, which resolved after 50 mg IV diphenhydramine and 50 mg IV methylprednisolone. The patient tolerated a repeated fourth dose and doses 5 and 6 in the continued desensitization. The pruritus returned after administration of dose 7, which was managed with 25 mg IV diphenhydramine. A subsequent, repeated dose 7, in addition to doses 8, 9, and 10, was administered without adverse effects. Full-body pruritus returned during dose 11 and was managed the same as the latter anaphylactoid reaction. The repeated dose 11, in addition to doses 12 and 13, was also well-tolerated. Dose 13 was repeated (ie, dose 14) to accommodate a brief delay in cardiac catheterization, contrary to the repetition of doses 4 and 8 as reported in Uppal et al.^[@bibr2-2152656719892844]^ Although readministration of the final dose was considered in the protocol described by Uppal et al. to avoid contrast-induced nephropathy (CIN),^[@bibr2-2152656719892844]^ our risk score calculations suggested that the patient was at low risk of nephropathy that did not necessitate reduced dosage.^[@bibr5-2152656719892844]^ This RCM desensitization was conducted in an intensive care unit. No complications were reported following catheterization.
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  Dose^[a](#table-fn1-2152656719892844){ref-type="table-fn"}^   Dilution   Concentration (mg/mL)   Dose (mg)   Volume (mL)
  ------------------------------------------------------------- ---------- ----------------------- ----------- -------------
  1                                                             1:10 000   0.032                   0.160       5
  2                                                             1:5000     0.064                   0.320       5
  3                                                             1:1000     0.320                   1.600       5
  4                                                             1:500      0.625                   3.125       5
  5                                                             1:250      1.250                   6.250       5
  6                                                             1:125      2.500                   12.50       5
  7                                                             1:62.5     5.000                   25.00       5
  8                                                             1:32       10.00                   50.00       5
  9                                                             1:16       20.00                   100.0       5
  10                                                            1:8        40.00                   200.0       5
  11                                                            1:4        80.00                   400.0       5
  12                                                            1:2        160.0                   800.0       5
  13                                                            1:1        320.0                   1600        5
  14^[b](#table-fn2-2152656719892844){ref-type="table-fn"}^     1:1        320.0                   1600        5
  15^[c](#table-fn3-2152656719892844){ref-type="table-fn"}^     --         --                      --          --

^a^10-minute intervals between dosages.

^b^Addition to protocol described in Uppal et al.; repetition of dose 13.

^c^Future dosage(s), if indicated.

Discussion {#sec3-2152656719892844}
==========

Anaphylactoid events mimic anaphylaxis, which is a life-threatening, systemic Type I hypersensitivity reaction occurring after exposure to an allergen, leading to multiorgan system involvement.^[@bibr6-2152656719892844][@bibr7-2152656719892844]--[@bibr8-2152656719892844]^ By definition, anaphylaxis affects 2 or more organ systems, including dermatological, respiratory, cardiovascular, gastrointestinal, and/or neurological with or without autonomic dysfunction.^[@bibr6-2152656719892844][@bibr7-2152656719892844]--[@bibr8-2152656719892844]^ Anaphylactoid reactions involve nonspecific activation of the complement system, in contrast to the immunoglobulin E (Ig E)-mediated mechanisms attributed to anaphylaxis.^[@bibr7-2152656719892844],[@bibr8-2152656719892844]^ Agents associated with non-IgE-mediated adverse reactions include plasma expanders (eg, Dextran, hydroxyethyl starch), opioids, nonbarbiturate hypnotics, and RCM.^[@bibr1-2152656719892844]^

Anaphylactoid and IgE-mediated reactions to RCM are uncommon, estimating 5% to 8% of the 10 million radiologic examinations performed annually in the United States.^[@bibr1-2152656719892844],[@bibr10-2152656719892844][@bibr11-2152656719892844]--[@bibr12-2152656719892844]^ Approximately 1% of patients receiving RCM experience moderate reactions, including acute vomiting, urticaria, and/or angioedema.^[@bibr2-2152656719892844]^ Life-threatening conditions, such as anaphylactoid reactions, manifest in less than 0.1% of patients traditionally with high-osmolality contrast.^[@bibr2-2152656719892844]^

CIN, or contrast-induced acute kidney injury (AKI), is a potential complication following cardiac angiography and is responsible for a third of hospital-acquired AKIs.^[@bibr5-2152656719892844]^ Preexistent clinical and periprocedural risk factors are considered in predicting CIN occurrence and guiding targeted preventative therapies.^[@bibr5-2152656719892844]^ The most significant preprocedural risk factor for CIN is stage III chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m^2^ for over 3 months.^[@bibr5-2152656719892844]^ Maioli et al.'s and Mehran et al.'s preprocedural and periprocedural CIN risk scores, assessing age, diabetes mellitus, eGFR, and other factors, were computed for the present patient and indicated low risk for CIN and dialysis.^[@bibr5-2152656719892844][@bibr6-2152656719892844]--[@bibr7-2152656719892844]^

Desensitization to biologic agents or other allergens is a standard preventative measure of anaphylactic and anaphylactoid events and is considered when patients present with history of anaphylaxis to the allergen of interest and no therapeutic alternative exists.^[@bibr2-2152656719892844]^ Limited literature offers data on successful RCM administration without adverse events for medical emergencies such as cardiac catheterization.^[@bibr1-2152656719892844],[@bibr3-2152656719892844],[@bibr4-2152656719892844]^ The present case demonstrates a common delay that occurs with cardiac catheterization and timing of desensitization to RCM

Although there has been a protocol published for rapid, successful desensitization to RCM,^[@bibr2-2152656719892844]^ accommodation for delayed cardiac catheterization has not been reported in the literature. The proposed desensitization schedule, although identical to Uppal et al.,^[@bibr2-2152656719892844]^ provides extra doses to the end of the protocol to accommodate the variable timing of the catheterization while maintaining the contrast quantitative amount to minimize CIN risk. Our protocol repeated the final dose, dose 13 ([Table 1](#table1-2152656719892844){ref-type="table"}), preventing postponement in the catheterization schedule. Ultimately, the need for cardiac catheterization supersedes the potential risk of nephrotoxicity, which may be offset by prehydration and pharmacological prophylaxis, if necessary. We describe a protocol that provides an additional dose to the desensitization process in order to accommodate cardiac catheterization delays.
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